friday nights thoughts, page-8

Hi Matt, the good thing in the first instance is we are looking at a return profile because there aren't too many Aussie biotechs out there in this position. The return profile will be influenced by the management but at the end of the day if the trial has clear benefit we'll all going to make good money.
There has been a lot of negative conjecture in recent times on this forum particularly around the possibility of another CR, but conjecture is all it is. I will stay in until facts convince me otherwise.